ClinicalTrials.gg
TerminatedNCT04026997Updated Mar 25, 2026Results posted

A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis

A Phase 2 interventional study of CIN-102 Dose 1 and CIN-102 Dose 2 in Gastroparesis, sponsored by CinDome Pharma, Inc.. Terminated at 19 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-03-25.

Sponsored by CinDome Pharma, Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
Terminated based on Sponsor decision due to lot recall of GEBT kits impacting the primary endpoint evaluation for Dose 2 and Dose 3.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 184 studies in Gastroparesis with a site in United States — 33 open to participants now, 41 under way, 2 of them phase 3. Gastroparesis · United States.

Enrollment
47th of 136
72 · median 36
Started
2019
with 16 others
Phase 2
38 of 184
none open now
Registered
110th of 184
by date
Lead sponsor
4 of 184
CinDome Pharma, Inc.

Among the 184 studies in Gastroparesis with a site in United States, this one is the 47th largest by enrollment of the 136 interventional ones that give a count, is one of 17 that started in 2019, is one of 38 in phase 2, and was the 110th registered.

Gastroparesis

323 studies on the registry are indexed under Gastroparesis; 75 are open to participants now.

Browse Gastroparesis studies →

Open to participants now

33 of the 184 studies in Gastroparesis with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 49 Gastroparesis studies recruiting now, 25 (51%) set no upper age limit and 14 (29%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 184 studies in Gastroparesis with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled Phase 2A study to evaluate safety, efficacy, PK, and dose response of oral CIN-102 in adults with idiopathic and diabetic gastroparesis. The study will assess three oral doses of CIN-102 versus placebo in three separate cohorts.

03

Conditions studied

  • Gastroparesis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients 18 to 70 years old.
  • Current diagnosis of idiopathic or diabetic gastroparesis OR documented delayed gastric emptying.
  • Presence of moderate to severe nausea.
  • (BMI) between 18 and 40 kg/m2, inclusive.
  • Glycosylated level \<11% at Screening.
  • Willing to washout from ongoing treatment for gastroparesis.
  • Able to understand and willing to comply with all study visits, procedures, restrictions, and provide written according to institutional and regulatory guidelines.

Exclusion criteria

Exclusion Criteria:

  • Other known disorder or treatment which could explain or contribute to symptoms of gastroparesis.
  • Positive test for drugs of abuse at the screening or evaluation visits.
  • Personal or family history of prolonged heart rate-.
  • History or evidence of arrhythmia.
  • History of gastrectomy, fundoplication, vagotomy, pyloroplasty, or bariatric surgery.
  • Females who are pregnant, nursing, or planning on becoming pregnant during the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Cohort 1

    CIN-102 tablets by mouth twice daily for 14 days

    Drug: CIN-102 Dose 1

  • Placebo comparator
    Cohort 1 - Placebo

    Placebo tablets by mouth twice daily for 14 days

    Drug: Placebo

  • Experimental
    Cohort 2

    CIN-102 tablets by mouth twice daily for 14 days

    Drug: CIN-102 Dose 2

  • Placebo comparator
    Cohort 2- Placebo

    Placebo tablets by mouth twice daily for 14 days

    Drug: Placebo

  • Experimental
    Cohort 3

    CIN-102 tablets by mouth twice daily for 14 days

    Drug: CIN-102 Dose 3

  • Active comparator
    Cohort 3- Placebo

    Placebo tablets by mouth twice daily for 14 days

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. The Change From Baseline in Gastric Emptying (GE) as Measured by the Gastric Emptying Breath Test (GEBT) Half-Time (T1/2)

    The GEBT is a nonradioactive, noninvasive, orally administered test for measuring the rate of solid phase gastric emptying (GE), after consumption of a standardized 13C-enriched meal. GEBT T1/2 is the time for half of the ingested meal to leave the stomach. It is reported using kPCD, a mathematical expression of a test subject's 13CO2 excretion rate per minute at any measurement time t relative to the dose of 13C contained in the test meal.

    Time frame: Baseline (gathered between Days -10 to -3, prior to first dose of study drug) to Day 14

  2. The Percent Change From Baseline in Gastric Emptying (GE) as Measured by the Gastric Emptying Breath Test (GEBT) Half-Time (T1/2)

    The GEBT is a nonradioactive, noninvasive, orally administered test for measuring the rate of solid phase gastric emptying (GE), after consumption of a standardized 13C-enriched meal. GEBT T1/2 is the time for half of the ingested meal to leave the stomach. It is reported using kPCD, a mathematical expression of a test subject's 13CO2 excretion rate per minute at any measurement time t relative to the dose of 13C contained in the test meal.

    Time frame: Baseline (gathered between Days -10 to -3, prior to first dose of study drug) to Day 14

Secondary outcomes

  1. The Change From Baseline in GE as Measured by the GEBT Excretion Rate

    The value and change from baseline in GEBT excretion rate (kPCD per minute) were summarized by treatment group. The value and time-matched (to baseline visit) change from baseline of the GEBT results for each post-meal time point were also summarized by treatment group.

    Time frame: Baseline (gathered between Days -10 to -3, prior to first dose of study drug) to Day 14

  2. The Percent Change From Baseline in GE as Measured by the GEBT Excretion Rate

    The percent change from baseline in GEBT excretion rate (kPCD per minute) was summarized by treatment group. The percent change from baseline of the GEBT results for each post-meal time point was also summarized by treatment group.

    Time frame: Baseline (gathered between Days -10 to -3, prior to first dose of study drug) to Day 14

  3. The Change From Baseline in ANMS GCSI-DD Total Scores

    American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD) total and subscale scores and change from baseline for the Intent to Treat Population using the protocol-specified scoring method and the manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

    Time frame: Baseline (mean score for the 3 days preceding randomization) to Day 14

  4. The Percent Change From Baseline in ANMS GCSI-DD Total Scores

    American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary(ANMS GCSI-DD) total and subscale scores percent change from baseline for the Intent to Treat Population using the protocol-specified scoring method and the manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

    Time frame: Baseline (mean score for the 3 days preceding randomization) to Day 14

  5. The Change From Baseline in ANMS GCSI-DD Subscale Scores - Upper Abdominal Pain

    American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD) subscale scores and change from baseline for the Intent to Treat Population using the manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

    Time frame: Baseline (mean score for the 3 days preceding randomization) to Day 14

  6. The Percent Change From Baseline in ANMS GCSI-DD Subscale Scores - Upper Abdominal Pain

    American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary(ANMS GCSI-DD) subscale scores percent change from baseline for the Intent to Treat Population using the protocol-specified scoring method and the manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

    Time frame: Baseline (mean score for the 3 days preceding randomization) to Day 14

  7. The Change From Baseline in ANMS GCSI-DD Subscale Scores - Bloating Subscale Score

    American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD) subscale scores and change from baseline for the Intent to Treat Population using the protocol-specified scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

    Time frame: Baseline (mean score for the 3 days preceding randomization) to Day 14

  8. The Percent Change From Baseline in ANMS GCSI-DD Subscale Scores - Bloating Subscale Score

    American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary(ANMS GCSI-DD) subscale scores percent change from baseline for the Intent to Treat Population using the protocol-specified scoring method and the manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

    Time frame: Baseline (mean score for the 3 days preceding randomization) to Day 14

  9. The Change From Baseline in ANMS GCSI-DD Subscale Scores - Nausea/Vomiting

    American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD) subscale scores and change from baseline for the Intent to Treat Population using the protocol-specified scoring method and manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

    Time frame: Baseline (mean score for the 3 days preceding randomization) to Day 14

  10. The Percent Change From Baseline in ANMS GCSI-DD Subscale Scores - Nausea/Vomiting

    American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary(ANMS GCSI-DD) subscale scores percent change from baseline for the Intent to Treat Population using the protocol-specified scoring method and the manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

    Time frame: Baseline (mean score for the 3 days preceding randomization) to Day 14

  11. The Change From Baseline in ANMS GCSI-DD Subscale Scores - Postprandial Fullness/Early Satiety

    American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD) subscale scores and change from baseline for the Intent to Treat Population using the protocol-specified scoring method and manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

    Time frame: Baseline (mean score for the 3 days preceding randomization) to Day 14 (+/- 2 days)

  12. The Percent Change From Baseline in ANMS GCSI-DD Subscale Scores - Postprandial Fullness/Early Satiety

    American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary(ANMS GCSI-DD) subscale scores percent change from baseline for the Intent to Treat Population using the protocol-specified scoring method and the manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

    Time frame: Baseline (mean score for the 3 days preceding randomization) to Day 14 (+/- 2 days)

  13. Pharmacokinetics (PK) Characterization of Multiple Doses of CIN-102: Maximum Observed Concentration (CMAX) - Day 1

    CMAX is defined as the maximum observed drug concentration after administration.

    Time frame: Day 1 (single dose)

  14. Pharmacokinetics (PK) Characterization of Multiple Doses of CIN-102: Maximum Observed Concentration (CMAX) - Day 14

    CMAX is defined as the maximum observed drug concentration after administration.

    Time frame: Day 14 (steady state)

  15. Pharmacokinetics (PK) Characterization of Multiple Doses of CIN-102: Time of Occurrence of CMAX (TMAX) - Day 14

    TMAX is defined as the time to maximum plasma concentration.

    Time frame: Day 14 (steady state)

  16. Pharmacokinetics (PK) Characterization of Multiple Doses of CIN-102: Time of Occurrence of CMAX (TMAX) - Day 1

    TMAX is defined as the time to maximum plasma concentration.

    Time frame: Day 1 (single dose)

  17. Pharmacokinetics (PK) Characterization of Multiple Doses of CIN-102: Area Under the Plasma Concentration-time Curve From Pre-dose (Time 0) to 12 Hours (AUC0-12)

    AUC0-12 is defined as the area under the plasma concentration-time curve from pre-dose (Time 0) to 12 Hours on Day 1 of CIN-102 dosing.

    Time frame: Day 1 (single dose), Time 0 to 12 hours

  18. Pharmacokinetics (PK) Characterization of Multiple Doses of CIN-102: Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUCtau)

    AUCtau is defined as the area under the plasma concentration-time curve over the dosing interval.

    Time frame: Day 14 (steady state)

Other outcomes

  1. The Change From Baseline in PAGI-SYM Total Score

    Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) total score and change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

    Time frame: Baseline (last available assessment prior to the first dose of study drug) to Day 14

  2. The Percent Change From Baseline in PAGI-SYM Total Score

    Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) total score percent change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

    Time frame: Baseline (last available assessment prior to the first dose of study drug) to Day 14

  3. The Change From Baseline in PAGI-SYM Subscale Score - Heartburn/Regurgitation

    Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score and change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

    Time frame: Baseline (last available assessment prior to the first dose of study drug) to Day 14

  4. The Percent Change From Baseline in PAGI-SYM Subscale Score - Heartburn/Regurgitation

    Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score percent change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

    Time frame: Baseline (last available assessment prior to the first dose of study drug) to Day 14

  5. The Change From Baseline in PAGI-SYM Subscale Score - Fullness/Early Satiety

    Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score and change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

    Time frame: Baseline (last available assessment prior to the first dose of study drug) to Day 14

  6. The Percent Change From Baseline in PAGI-SYM Subscale Score - Fullness/Early Satiety

    Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score percent change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

    Time frame: Baseline (last available assessment prior to the first dose of study drug) to Day 14

  7. The Change From Baseline in PAGI-SYM Subscale Score - Nausea/Vomiting

    Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score and change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

    Time frame: Baseline (last available assessment prior to the first dose of study drug) to Day 14

  8. The Percent Change From Baseline in PAGI-SYM Subscale Score - Nausea/Vomiting

    Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score percent change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

    Time frame: Baseline (last available assessment prior to the first dose of study drug) to Day 14

  9. The Change From Baseline in PAGI-SYM Subscale Score - Bloating

    Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score and change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

    Time frame: Baseline (last available assessment prior to the first dose of study drug) to Day 14

  10. The Percent Change From Baseline in PAGI-SYM Subscale Score - Bloating

    Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score percent change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

    Time frame: Baseline (last available assessment prior to the first dose of study drug) to Day 14

  11. The Change From Baseline in PAGI-SYM Subscale Scores - Upper Abdominal Pain

    Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score and change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

    Time frame: Baseline (last available assessment prior to the first dose of study drug) to Day 14

  12. The Percent Change From Baseline in PAGI-SYM Subscale Scores - Upper Abdominal Pain

    Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score percent change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

    Time frame: Baseline (last available assessment prior to the first dose of study drug) to Day 14

  13. The Change From Baseline in PAGI-SYM Subscale Score - Lower Abdominal Pain

    Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score and change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

    Time frame: Baseline (last available assessment prior to the first dose of study drug) to Day 14

  14. The Percent Change From Baseline in PAGI-SYM Subscale Score - Lower Abdominal Pain

    Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score percent change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

    Time frame: Baseline (last available assessment prior to the first dose of study drug) to Day 14

  15. Clinical Grading Assessment Scale at Day 14

    The Clinical Grading Assessment Scale is a patient and investigator reported outcome instrument for a clinical trial endpoint. Completed at Day 14, the assessment asks subjects about how their stomach/gastroparesis-related problems/symptoms compare to the period before they started treatment in the study based on a 15-point likert scale, where +7 is completely better, 0 is no change, and -7 is very much worse.

    Time frame: Day 14

07

Results

Posted Mar 25, 2026
Limitations and caveats
Due to the recall of GEBT kits for 11 subjects in Cohort 2 and all subjects in Cohort 3, GEBT data for these subjects were not used, and the study was terminated early by Sponsor decision on 08 January 2021 prior to enrolling the full anticipated Cohort 3 because the primary endpoint was now null.

Participant flow

This study was initiated on 11 September 2019 and completed on 17 December 2020 across 15 clinical sites in the United States (US). A total of 60 participants with idiopathic or diabetic gastroparesis were planned to be enrolled.

Participant flow — Overall Study
MilestoneCohort 1 - 10 mg BIDCohort 2 - 20 mg QDCohort 3 - 5 mg BIDPlacebo (Pooled)
Started3015918
Completed2915918
Not completed1000
Withdrew: Randomized in error by the site1000

Outcome measures

PrimaryThe Change From Baseline in Gastric Emptying (GE) as Measured by the Gastric Emptying Breath Test (GEBT) Half-Time (T1/2)

The GEBT is a nonradioactive, noninvasive, orally administered test for measuring the rate of solid phase gastric emptying (GE), after consumption of a standardized 13C-enriched meal. GEBT T1/2 is the time for half of the ingested meal to leave the stomach. It is reported using kPCD, a mathematical expression of a test subject's 13CO2 excretion rate per minute at any measurement time t relative to the dose of 13C contained in the test meal.

Time frame:
Baseline (gathered between Days -10 to -3, prior to first dose of study drug) to Day 14
Reported as:
Mean · Minutes
The Change From Baseline in Gastric Emptying (GE) as Measured by the Gastric Emptying Breath Test (GEBT) Half-Time (T1/2)
MinutesCohort 1 - 10 mg BIDCohort 1 - PlaceboCohort 2 - 20 mg QDCohort 2- PlaceboCohort 3- 5 mg BIDCohort 3- Placebo
T 1/2 Baseline132.97 ± 36.228119 ± 34.654123.25 ± 34.394138.07 ± 54.684162.90 ± 12.587—
T 1/2 Day 14123.16 ± 30.881111.45 ± 20.923125.70 ± 44.190197.80——
T 1/2 Change from baseline to Day 14-10.60 ± 37.240-8.05 ± 35.640-12.37 ± 17.6216.20——
PrimaryThe Percent Change From Baseline in Gastric Emptying (GE) as Measured by the Gastric Emptying Breath Test (GEBT) Half-Time (T1/2)

The GEBT is a nonradioactive, noninvasive, orally administered test for measuring the rate of solid phase gastric emptying (GE), after consumption of a standardized 13C-enriched meal. GEBT T1/2 is the time for half of the ingested meal to leave the stomach. It is reported using kPCD, a mathematical expression of a test subject's 13CO2 excretion rate per minute at any measurement time t relative to the dose of 13C contained in the test meal.

Time frame:
Baseline (gathered between Days -10 to -3, prior to first dose of study drug) to Day 14
Reported as:
Mean · Percent change in GE time
The Percent Change From Baseline in Gastric Emptying (GE) as Measured by the Gastric Emptying Breath Test (GEBT) Half-Time (T1/2)
Percent change in GE timeCohort 1 - 10 mg BIDCohort 1 - PlaceboCohort 2 - 20 mg QDCohort 2- PlaceboCohort 3- 5 mg BIDCohort 3- Placebo
The Percent Change From Baseline in Gastric Emptying (GE) as Measured by the Gastric Emptying Breath Test (GEBT) Half-Time (T1/2)-4.23 ± 24.278-1.35 ± 26.533-9.27 ± 11.3043.24——
SecondaryThe Change From Baseline in GE as Measured by the GEBT Excretion Rate

The value and change from baseline in GEBT excretion rate (kPCD per minute) were summarized by treatment group. The value and time-matched (to baseline visit) change from baseline of the GEBT results for each post-meal time point were also summarized by treatment group.

Time frame:
Baseline (gathered between Days -10 to -3, prior to first dose of study drug) to Day 14
Reported as:
Mean · kPCD min-1
The Change From Baseline in GE as Measured by the GEBT Excretion Rate
kPCD min-1Cohort 1- 10 mg BIDCohort 1 - PlaceboCohort 2- 20 mg QDCohort 2- PlaceboCohort 3- 5 mg BIDCohort 3- Placebo
GEBT 45 minutes post meal consumption - Baseline8.88 ± 4.1139.56 ± 6.04011.39 ± 3.6808.37 ± 5.1327.50 ± 4.950—
GEBT 45 minutes post meal consumption - Day 1410.74 ± 3.03810.70 ± 3.26610.39 ± 4.5344.10——
GEBT 45 minutes post meal consumption - Change from Baseline to Day 141.96 ± 4.0911.14 ± 6.210-1.07 ± 3.4751.40——
GEBT 90 minutes post meal consumption - Baseline20.53 ± 9.01623.55 ± 10.52223.30 ± 9.34923.10 ± 12.44316.75 ± 10.960—
GEBT 90 minutes post meal consumption - Day 1423.60 ± 6.12825.10 ± 6.55122.01 ± 10.8894.20——
GEBT 90 minutes post meal consumption - Change from baseline to Day 143.37 ± 9.2871.55 ± 10.0561.96 ± 5.962-8.80——
GEBT 120 minutes post meal consumption - Baseline29.02 ± 11.54931.45 ± 12.53631.04 ± 12.26421.453 ± 25.6021.50 ± 7.212—
GEBT 120 minutes post meal consumption - Day 1432.68 ± 8.90133.61 ± 9.14632.40 ± 14.6787.20——
GEBT 120 minutes post meal consumption - Change from baseline to Day 143.86 ± 11.0082.16 ± 11.5476.03 ± 7.958-6.30——
GEBT 150 minutes post meal consumption - Baseline35.97 ± 12.94636.89 ± 11.82037.94 ± 13.85536.33 ± 23.42725.90 ± 0.849—
GEBT 150 minutes post meal consumption - Day 1437.13 ± 10.00239.23 ± 8.02135.30 ± 16.4888.90——
GEBT 150 minutes post meal consumption - Change from baseline to Day 141.25 ± 12.2612.34 ± 10.3242.46 ± 7.241-6.80——
GEBT 180 minutes post meal consumption - Baseline39.02 ± 13.25840.94 ± 12.52640.66 ± 12.53638.70 ± 20.04430.70 ± 7.778—
GEBT 180 minutes post meal consumption - Day 1440.96 ± 11.08043.67 ± 8.07836.91 ± 14.39815.20——
GEBT 180 minutes post meal consumption - Change from baseline to Day 141.85 ± 12.4452.74 ± 10.9590.37 ± 5.949-5.50——
GEBT 240 minutes post meal consumption - Baseline41.89 ± 12.75041.85 ± 8.95342.07 ± 11.95140.50 ± 9.00029.85 ± 13.223—
GEBT 240 minutes post meal consumption - Day 1441.41 ± 10.42244.57 ± 7.92837.28 ± 10.67920.40——
GEBT 240 minutes post meal consumption - Change from baseline to Day 14-0.79 ± 11.8212.73 ± 8.144-3.34 ± 5.496-11.10——
SecondaryThe Percent Change From Baseline in GE as Measured by the GEBT Excretion Rate

The percent change from baseline in GEBT excretion rate (kPCD per minute) was summarized by treatment group. The percent change from baseline of the GEBT results for each post-meal time point was also summarized by treatment group.

Time frame:
Baseline (gathered between Days -10 to -3, prior to first dose of study drug) to Day 14
Reported as:
Mean · Percent change in GEBT excretion rate
The Percent Change From Baseline in GE as Measured by the GEBT Excretion Rate
Percent change in GEBT excretion rateCohort 1- 10 mg BIDCohort 1 - PlaceboCohort 2- 20 mg QDCohort 2- PlaceboCohort 3- 5 mg BIDCohort 3- Placebo
GEBT 45 minutes post meal consumption - Percent change from Baseline to Day 1489.31 ± 266.803-679.95 ± 2500.333-7.99 ± 28.24351.85——
GEBT 90 minutes post meal consumption - Percent change from baseline to Day 1456.73 ± 125.21843.43 ± 117.79615.73 ± 41.144-67.69——
GEBT 120 minutes post meal consumption - Percent change from baseline to Day 1440.17 ± 102.99429.78 ± 83.47625.37 ± 34.722-46.67——
GEBT 150 minutes post meal consumption - Percent change from baseline to Day 1423.46 ± 82.60921.57 ± 64.6147.78 ± 23.087-43.31——
GEBT 180 minutes post meal consumption - Percent change from baseline to Day 1420.31 ± 65.49117.80 ± 46.4881.40 ± 15.573-26.57——
GEBT 240 minutes post meal consumption - Percent change from baseline to Day 149.46 ± 58.5679.87 ± 25.864-5.31 ± 18.076-35.24——
SecondaryThe Change From Baseline in ANMS GCSI-DD Total Scores

American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD) total and subscale scores and change from baseline for the Intent to Treat Population using the protocol-specified scoring method and the manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

Time frame:
Baseline (mean score for the 3 days preceding randomization) to Day 14
Reported as:
Mean · score on a scale
The Change From Baseline in ANMS GCSI-DD Total Scores
score on a scaleCohort 1 - 10 mg BIDCohort 1 - PlaceboCohort 2 - 20 mg QDCohort 2- PlaceboCohort 3- 5 mg BIDCohort 3- Placebo
Protocol Scoring Method - Baseline2.42 ± 0.6662.40 ± 0.4642.40 ± 0.5302.33 ± 0.2762.33 ± 0.5832.81 ± 0.594
Protocol Scoring Method - Day 141.40 ± 0.7311.23 ± 0.8701.08 ± 0.8660.83 ± 0.6941.78 ± 1.0511.33 ± 0.882
Protocol Scoring Method - Change from baseline to Day 14-1.04 ± 0.612-1.18 ± 0.754-1.33 ± 0.864-1.50 ± 0.803-0.56 ± 0.665-1.48 ± 1.233
Manual Scoring Method - Baseline2.14 ± 0.9542.15 ± 0.4142.13 ± 0.4952.18 ± 0.4502.16 ± 0.5672.56 ± 0.454
Manual Scoring Method - Day 141.17 ± 0.5821.04 ± 0.8330.88 ± 0.6710.80 ± 0.7301.47 ± 1.0821.20 ± 0.693
Manual Scoring Method - Change from baseline to Day 14-0.98 ± 0.684-1.11 ± 0.699-1.25 ± 0.831-1.38 ± 0.672-0.69 ± 0.736-1.36 ± 0.707
SecondaryThe Percent Change From Baseline in ANMS GCSI-DD Total Scores

American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary(ANMS GCSI-DD) total and subscale scores percent change from baseline for the Intent to Treat Population using the protocol-specified scoring method and the manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

Time frame:
Baseline (mean score for the 3 days preceding randomization) to Day 14
Reported as:
Mean · Percent change in score
The Percent Change From Baseline in ANMS GCSI-DD Total Scores
Percent change in scoreCohort 1- 10 mg BIDCohort 1 - PlaceboCohort 2- 20 mg QDCohort 2- PlaceboCohort 3- 5 mg BIDCohort 3- Placebo
Protocol Scoring Method - Percent change from baseline to Day 14-43.64 ± 24.813-49.45 ± 33.736-55.24 ± 35.011-63.25 ± 34.016-26.84 ± 31.291-48.79 ± 40.507
Manual Scoring Method - Percent change from baseline to Day 14-44.07 ± 26.803-52.61 ± 33.887-55.99 ± 35.840-65.05 ± 34.164-35.01 ± 36.277-52.81 ± 28.361
SecondaryThe Change From Baseline in ANMS GCSI-DD Subscale Scores - Upper Abdominal Pain

American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD) subscale scores and change from baseline for the Intent to Treat Population using the manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

Time frame:
Baseline (mean score for the 3 days preceding randomization) to Day 14
Reported as:
Mean · score on a scale
The Change From Baseline in ANMS GCSI-DD Subscale Scores - Upper Abdominal Pain
score on a scaleCohort 1 - 10 mg BIDCohort 1 - PlaceboCohort 2 - 20 mg QDCohort 2- PlaceboCohort 3 - 5 mg BIDCohort 3- Placebo
Manual Scoring Method - Baseline1.79 ± 1.1601.94 ± 0.8411.96 ± 0.8722.08 ± 0.8332.19 ± 1.0422.11 ± 1.171
Manual Scoring Method - Day 140.97 ± 0.9060.73 ± 0.7860.87 ± 0.7431.00 ± 1.1551.33 ± 1.4141.33 ± 1.155
Manual Scoring Method - Change from baseline to Day 14-0.80 ± 1.093-1.21 ± 0.981-1.09 ± 1.065-1.08 ± 0.957-0.85 ± 0.988-0.78 ± 0.694
SecondaryThe Percent Change From Baseline in ANMS GCSI-DD Subscale Scores - Upper Abdominal Pain

American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary(ANMS GCSI-DD) subscale scores percent change from baseline for the Intent to Treat Population using the protocol-specified scoring method and the manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

Time frame:
Baseline (mean score for the 3 days preceding randomization) to Day 14
Reported as:
Mean · Percent change in score
The Percent Change From Baseline in ANMS GCSI-DD Subscale Scores - Upper Abdominal Pain
Percent change in scoreCohort 1 - 10 mg BIDCohort 1 - PlaceboCohort 2 - 20 mg QDCohort 2- PlaceboCohort 3- 5 mg BIDCohort 3- Placebo
The Percent Change From Baseline in ANMS GCSI-DD Subscale Scores - Upper Abdominal Pain-50.43 ± 47.000-59.74 ± 44.230-41.03 ± 79.068-58.33 ± 50.000-43.15 ± 45.854-46.67 ± 50.332
SecondaryThe Change From Baseline in ANMS GCSI-DD Subscale Scores - Bloating Subscale Score

American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD) subscale scores and change from baseline for the Intent to Treat Population using the protocol-specified scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

Time frame:
Baseline (mean score for the 3 days preceding randomization) to Day 14
Reported as:
Mean · score on a scale
The Change From Baseline in ANMS GCSI-DD Subscale Scores - Bloating Subscale Score
score on a scaleCohort 1 - 10 mg BIDCohort 1 - PlaceboCohort 2 - 20 mg QDCohort 2- PlaceboCohort 3 - 5 mg BIDCohort 3- Placebo
Protocol Specified Scoring Method - Baseline2.80 ± 0.8242.82 ± 0.4802.87 ± 0.7102.58 ± 0.5002.70 ± 0.6963.11 ± 1.018
Protocol Specified Scoring Method - Day 141.76 ± 1.1231.45 ± 0.9341.47 ± 1.3561.00 ± 0.8162.33 ± 1.1181.67 ± 1.518
Protocol Specified Scoring Method - Change from baseline to Day 14-1.08 ± 0.785-1.36 ± 0.994-1.40 ± 1.121-1.58 ± 1.258-0.37 ± 0.655-1.44 ± 2.219
SecondaryThe Percent Change From Baseline in ANMS GCSI-DD Subscale Scores - Bloating Subscale Score

American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary(ANMS GCSI-DD) subscale scores percent change from baseline for the Intent to Treat Population using the protocol-specified scoring method and the manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

Time frame:
Baseline (mean score for the 3 days preceding randomization) to Day 14
Reported as:
Mean · Percent change in score
The Percent Change From Baseline in ANMS GCSI-DD Subscale Scores - Bloating Subscale Score
Percent change in scoreCohort 1 - 10 mg BIDCohort 1 - PlaceboCohort 2 - 20 mg QDCohort 2- PlaceboCohort 3 - 5 mg BIDCohort 3- Placebo
The Percent Change From Baseline in ANMS GCSI-DD Subscale Scores - Bloating Subscale Score-41.78 ± 32.337-46.73 ± 35.270-51.82 ± 41.422-55.95 ± 41.582-16.16 ± 26.339-33.33 ± 76.376
SecondaryThe Change From Baseline in ANMS GCSI-DD Subscale Scores - Nausea/Vomiting

American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD) subscale scores and change from baseline for the Intent to Treat Population using the protocol-specified scoring method and manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

Time frame:
Baseline (mean score for the 3 days preceding randomization) to Day 14
Reported as:
Mean · score on a scale
The Change From Baseline in ANMS GCSI-DD Subscale Scores - Nausea/Vomiting
score on a scaleCohort 1 - 10 mg BIDCohort 1 - PlaceboCohort 2 - 20 mg QDCohort 2- PlaceboCohort 3Cohort 3- Placebo
Protocol Scoring Method - Baseline1.62 ± 0.7521.55 ± 0.7571.60 ± 0.6231.79 ± 0.7981.52 ± 0.5562.00 ± 0.500
Protocol Scoring Method - Day 140.74 ± 0.5610.59 ± 1.0200.40 ± 0.4310.38 ± 0.4791.00 ± 1.0610.50 ± 0.500
Protocol Scoring Method - Change from baseline to Day 14-0.89 ± 0.820-0.95 ± 0.583-1.20 ± 0.812-1.42 ± 0.776-0.52 ± 0.719-1.50 ± 0.866
Manual Scoring Method - Nausea Baseline2.52 ± 0.7862.45 ± 0.5632.67 ± 0.8542.33 ± 0.9032.59 ± 0.7783.00 ± 0.000
Manual Scoring Method - Nausea Day 141.34 ± 1.0100.82 ± 0.9820.73 ± 0.7990.75 ± 0.9571.67 ± 1.3231.00 ± 1.000
Manual Scoring Method - Nausea Change from baseline to Day 14-1.20 ± 0.994-1.64 ± 0.912-1.93 ± 1.476-1.58 ± 0.788-0.93 ± 0.997-2.00 ± 1.000
Manual Scoring Method - Vomiting Baseline0.71 ± 1.0200.64 ± 1.2060.53 ± 0.7641.25 ± 0.9180.44 ± 0.5771.00 ± 1.000
Manual Scoring Method - Vomiting Day 140.14 ± 0.3510.36 ± 1.2060.07 ± 0.2580.00 ± 0.0000.33 ± 1.0000.00 ± 0.000
Manual Scoring Method - Vomiting Change from baseline to Day 14-0.59 ± 0.937-0.27 ± 0.467-0.47 ± 0.627-1.25 ± 0.918-0.11 ± 0.645-1.00 ± 1.000
SecondaryThe Percent Change From Baseline in ANMS GCSI-DD Subscale Scores - Nausea/Vomiting

American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary(ANMS GCSI-DD) subscale scores percent change from baseline for the Intent to Treat Population using the protocol-specified scoring method and the manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

Time frame:
Baseline (mean score for the 3 days preceding randomization) to Day 14
Reported as:
Mean · Percent change in score
The Percent Change From Baseline in ANMS GCSI-DD Subscale Scores - Nausea/Vomiting
Percent change in scoreCohort 1 - 10 mg BIDCohort 1 - PlaceboCohort 2 - 20 mg QDCohort 2- PlaceboCohort 3Cohort 3- Placebo
Protocol Scoring Method - Percent change from baseline to Day 14-52.41 ± 37.374-69.49 ± 38.394-67.94 ± 34.799-81.36 ± 25.729-41.08 ± 47.221-72.22 ± 25.459
Manual Scoring Method - Nausea Percent change from baseline to Day 14-48.88 ± 37.271-68.35 ± 38.39938.399 ± 42.230-73.96 ± 32.342-41.32 ± 43.189-66.67 ± 33.333
Manual Scoring Method - Vomiting Percent Change from baseline to Day 14-71.73 ± 75.756-80.00 ± 44.721-94.64 ± 15.152-100.00 ± 0.000-64.00 ± 80.498-100.00 ± 0.000
SecondaryThe Change From Baseline in ANMS GCSI-DD Subscale Scores - Postprandial Fullness/Early Satiety

American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD) subscale scores and change from baseline for the Intent to Treat Population using the protocol-specified scoring method and manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

Time frame:
Baseline (mean score for the 3 days preceding randomization) to Day 14 (+/- 2 days)
Reported as:
Mean · score on a scale
The Change From Baseline in ANMS GCSI-DD Subscale Scores - Postprandial Fullness/Early Satiety
score on a scaleCohort 1 - 10 mg BIDCohort 1 - PlaceboCohort 2 - 20 mg QDCohort 2- PlaceboCohort 3Cohort 3- Placebo
Protocol Specified Scoring Method - Baseline2.84 ± 0.6742.85 ± 0.5752.74 ± 0.6302.63 ± 0.2502.78 ± 0.7913.33 ± 0.577
Protocol Specified Scoring Method - Day 141.71 ± 0.9781.64 ± 1.0271.37 ± 1.0081.13 ± 0.8542.00 ± 1.1461.83 ± 0.764
Protocol Specified Scoring Method - Change from baseline to Day 14-1.16 ± 0.771-1.21 ± 0.961-1.38 ± 1.011-1.50 ± 1.080-0.78 ± 0.816-1.50 ± 0.866
Manual Scoring Method - Postprandial fullness Baseline3.01 ± 0.6343.00 ± 0.4712.84 ± 0.7952.75 ± 0.1672.93 ± 0.7603.44 ± 0.509
Manual Scoring Method - Postprandial fullness Day 141.79 ± 1.0821.73 ± 1.1911.53 ± 1.1251.25 ± 0.9572.22 ± 1.3022.00 ± 1.000
Manual Scoring Method - Postprandial fullness Change from baseline to Day 14-1.24 ± 0.917-1.27 ± 1.114-1.31 ± 1.116-1.50 ± 1.106-0.70 ± 1.033-1.44 ± 1.262
Manual Scoring Method - Early satiety Baseline2.67 ± 0.7832.70 ± 0.7222.64 ± 0.5562.50 ± 0.4302.63 ± 0.8733.22 ± 0.694
Manual Scoring Method - Early satiety Day 141.62 ± 1.0151.55 ± 0.9341.20 ± 0.9411.00 ± 0.8161.78 ± 1.0931.67 ± 0.577
Manual Scoring Method - Early satiety Change from baseline to Day 14-1.08 ± 0.834-1.15 ± 0.911-1.44 ± 0.948-1.50 ± 1.139-0.85 ± 0.852-1.56 ± 0.509
SecondaryThe Percent Change From Baseline in ANMS GCSI-DD Subscale Scores - Postprandial Fullness/Early Satiety

American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary(ANMS GCSI-DD) subscale scores percent change from baseline for the Intent to Treat Population using the protocol-specified scoring method and the manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

Time frame:
Baseline (mean score for the 3 days preceding randomization) to Day 14 (+/- 2 days)
Reported as:
Mean · Percent change in score
The Percent Change From Baseline in ANMS GCSI-DD Subscale Scores - Postprandial Fullness/Early Satiety
Percent change in scoreCohort 1 - 10 mg BIDCohort 1 - PlaceboCohort 2 - 20 mg QDCohort 2- PlaceboCohort 3Cohort 3- Placebo
Protocol Specified Scoring Method - Percent change from baseline to Day 14-41.38 ± 29.096-42.32 ± 36.042-50.14 ± 36.594-54.75 ± 36.522-29.47 ± 32.944-44.44 ± 25.459
Manual Scoring Method - Postprandial fullness Percent change from baseline to Day 14-41.52 ± 33.646-42.90 ± 37.929-45.50 ± 38.815-53.13 ± 35.904-26.11 ± 38.424-40.00 ± 36.056
Manual Scoring Method - Early satiety Percent change from baseline to Day 14-40.56 ± 31.248-40.56 ± 41.704-54.88 ± 35.65155.95 ± 41.582-30.65 ± 38.876-48.61 ± 14.633
SecondaryPharmacokinetics (PK) Characterization of Multiple Doses of CIN-102: Maximum Observed Concentration (CMAX) - Day 1

CMAX is defined as the maximum observed drug concentration after administration.

Time frame:
Day 1 (single dose)
Reported as:
Mean · ng/mL
Pharmacokinetics (PK) Characterization of Multiple Doses of CIN-102: Maximum Observed Concentration (CMAX) - Day 1
ng/mLCohort 1 - 10 mg BIDCohort 2 - 20 mg QDCohort 3 - 5 mg BID
Pharmacokinetics (PK) Characterization of Multiple Doses of CIN-102: Maximum Observed Concentration (CMAX) - Day 110.066 ± 5.647425.460 ± 16.82126.730 ± 4.4942
SecondaryPharmacokinetics (PK) Characterization of Multiple Doses of CIN-102: Maximum Observed Concentration (CMAX) - Day 14

CMAX is defined as the maximum observed drug concentration after administration.

Time frame:
Day 14 (steady state)
Reported as:
Mean · ng/mL
Pharmacokinetics (PK) Characterization of Multiple Doses of CIN-102: Maximum Observed Concentration (CMAX) - Day 14
ng/mLCohort 1 - 10 mg BIDCohort 2 - 20 mg QDCohort 3 - 5 mg BID
Pharmacokinetics (PK) Characterization of Multiple Doses of CIN-102: Maximum Observed Concentration (CMAX) - Day 1418.176 ± 12.017836.407 ± 18.943112.276 ± 10.9355
SecondaryPharmacokinetics (PK) Characterization of Multiple Doses of CIN-102: Time of Occurrence of CMAX (TMAX) - Day 14

TMAX is defined as the time to maximum plasma concentration.

Time frame:
Day 14 (steady state)
Reported as:
Median · h
Pharmacokinetics (PK) Characterization of Multiple Doses of CIN-102: Time of Occurrence of CMAX (TMAX) - Day 14
hCohort 1 - 10 mg BIDCohort 2 - 20 mg QDCohort 3 - 5 mg BID
Pharmacokinetics (PK) Characterization of Multiple Doses of CIN-102: Time of Occurrence of CMAX (TMAX) - Day 142.000 (0.97 to 4.52)2.000 (1.00 to 6.00)2.000 (1.00 to 8.00)
SecondaryPharmacokinetics (PK) Characterization of Multiple Doses of CIN-102: Time of Occurrence of CMAX (TMAX) - Day 1

TMAX is defined as the time to maximum plasma concentration.

Time frame:
Day 1 (single dose)
Reported as:
Median · h
Pharmacokinetics (PK) Characterization of Multiple Doses of CIN-102: Time of Occurrence of CMAX (TMAX) - Day 1
hCohort 1 - 10 mg BIDCohort 2 - 20 mg QDCohort 3 - 5 mg BID
Pharmacokinetics (PK) Characterization of Multiple Doses of CIN-102: Time of Occurrence of CMAX (TMAX) - Day 12.000 (0.98 to 6.00)2.500 (1.00 to 6.00)2.000 (0.98 to 4.05)
SecondaryPharmacokinetics (PK) Characterization of Multiple Doses of CIN-102: Area Under the Plasma Concentration-time Curve From Pre-dose (Time 0) to 12 Hours (AUC0-12)

AUC0-12 is defined as the area under the plasma concentration-time curve from pre-dose (Time 0) to 12 Hours on Day 1 of CIN-102 dosing.

Time frame:
Day 1 (single dose), Time 0 to 12 hours
Reported as:
Mean · h*ng/mL
Pharmacokinetics (PK) Characterization of Multiple Doses of CIN-102: Area Under the Plasma Concentration-time Curve From Pre-dose (Time 0) to 12 Hours (AUC0-12)
h*ng/mLCohort 1 - 10 mg BIDCohort 2 - 20 mg QDCohort 3 - 5 mg BID
Pharmacokinetics (PK) Characterization of Multiple Doses of CIN-102: Area Under the Plasma Concentration-time Curve From Pre-dose (Time 0) to 12 Hours (AUC0-12)46.98 ± 22.861104.33 ± 52.26734.73 ± 20.907
SecondaryPharmacokinetics (PK) Characterization of Multiple Doses of CIN-102: Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUCtau)

AUCtau is defined as the area under the plasma concentration-time curve over the dosing interval.

Time frame:
Day 14 (steady state)
Reported as:
Mean · h*ng/mL
Pharmacokinetics (PK) Characterization of Multiple Doses of CIN-102: Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUCtau)
h*ng/mLCohort 1 - 10 mg BIDCohort 2 - 20 mg QDCohort 3 - 5 mg BID
Pharmacokinetics (PK) Characterization of Multiple Doses of CIN-102: Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUCtau)100.18 ± 59.796301.94 ± 149.49965.73 ± 34.822
Other pre-specifiedThe Change From Baseline in PAGI-SYM Total Score

Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) total score and change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

Time frame:
Baseline (last available assessment prior to the first dose of study drug) to Day 14
Reported as:
Mean · score on a scale
The Change From Baseline in PAGI-SYM Total Score
score on a scaleCohort 1 - 10 mg BIDCohort 1 - PlaceboCohort 2 - 20 mg QDCohort 2- PlaceboCohort 3 - 5 mg BIDCohort 3- Placebo
Baseline2.94 ± 0.6233.25 ± 0.4952.72 ± 0.8383.50 ± 0.2413.37 ± 0.6582.86 ± 0.198
Day 141.97 ± 0.8551.75 ± 0.9491.80 ± 1.2511.60 ± 1.3292.02 ± 1.3001.59 ± 0.638
Change from baseline to Day 14-0.97 ± 0.990-1.50 ± 1.312-0.93 ± 0.806-1.90 ± 1.286-1.35 ± 1.179-1.27 ± 0.660
Other pre-specifiedThe Percent Change From Baseline in PAGI-SYM Total Score

Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) total score percent change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

Time frame:
Baseline (last available assessment prior to the first dose of study drug) to Day 14
Reported as:
Mean · Percent change in score
The Percent Change From Baseline in PAGI-SYM Total Score
Percent change in scoreCohort 1 - 10 mg BIDCohort 1 - PlaceboCohort 2 - 20 mg QDCohort 2- PlaceboCohort 3 - 5 mg BIDCohort 3- Placebo
The Percent Change From Baseline in PAGI-SYM Total Score-31.18 ± 33.026-42.32 ± 35.140-39.03 ± 33.130-54.64 ± 37.449-40.13 ± 32.850-44.16 ± 21.761
Other pre-specifiedThe Change From Baseline in PAGI-SYM Subscale Score - Heartburn/Regurgitation

Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score and change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

Time frame:
Baseline (last available assessment prior to the first dose of study drug) to Day 14
Reported as:
Mean · score on a scale
The Change From Baseline in PAGI-SYM Subscale Score - Heartburn/Regurgitation
score on a scaleCohort 1 - 10 mg BIDCohort 1 - PlaceboCohort 2 - 20 mg QDCohort 2- PlaceboCohort 3 - 5 mg BIDCohort 3- Placebo
Baseline2.67 ± 1.1263.09 ± 0.8672.68 ± 1.1794.04 ± 0.4103.63 ± 0.7832.90 ± 1.110
Day 141.62 ± 1.2341.70 ± 1.0451.62 ± 1.4001.79 ± 0.9791.84 ± 1.3021.10 ± 0.436
Change from baseline to Day 14-1.07 ± 1.485-1.39 ± 1.659-1.06 ± 1.357-2.25 ± 1.247-1.79 ± 1.183-1.81 ± 1.164
Other pre-specifiedThe Percent Change From Baseline in PAGI-SYM Subscale Score - Heartburn/Regurgitation

Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score percent change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

Time frame:
Baseline (last available assessment prior to the first dose of study drug) to Day 14
Reported as:
Mean · Percent change in score
The Percent Change From Baseline in PAGI-SYM Subscale Score - Heartburn/Regurgitation
Percent change in scoreCohort 1 - 10 mg BIDCohort 1 - PlaceboCohort 2 - 20 mg QDCohort 2- PlaceboCohort 3 - 5 mg BIDCohort 3- Placebo
The Percent Change From Baseline in PAGI-SYM Subscale Score - Heartburn/Regurgitation-25.45 ± 69.985-16.23 ± 121.734-34.56 ± 78.627-54.50 ± 27.174-50.23 ± 29.032-59.68 ± 18.912
Other pre-specifiedThe Change From Baseline in PAGI-SYM Subscale Score - Fullness/Early Satiety

Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score and change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

Time frame:
Baseline (last available assessment prior to the first dose of study drug) to Day 14
Reported as:
Mean · score on a scale
The Change From Baseline in PAGI-SYM Subscale Score - Fullness/Early Satiety
score on a scaleCohort 1 - 10 mg BIDCohort 1 - PlaceboCohort 2 - 20 mg QDCohort 2- PlaceboCohort 3 - 5 mg BIDCohort 3- Placebo
Baseline3.60 ± 0.7923.70 ± 0.7143.42 ± 0.8593.63 ± 0.7773.89 ± 0.7823.50 ± 0.250
Day 142.71 ± 1.1092.27 ± 1.2222.32 ± 1.3211.75 ± 1.1732.36 ± 1.4262.25 ± 1.090
Change from baseline to Day 14-0.88 ± 0.915-1.43 ± 1.347-1.10 ± 1.224-1.88 ± 1.665-1.53 ± 1.422-1.25 ± 1.090
Other pre-specifiedThe Percent Change From Baseline in PAGI-SYM Subscale Score - Fullness/Early Satiety

Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score percent change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

Time frame:
Baseline (last available assessment prior to the first dose of study drug) to Day 14
Reported as:
Mean · Percent change in score
The Percent Change From Baseline in PAGI-SYM Subscale Score - Fullness/Early Satiety
Percent change in scoreCohort 1 - 10 mg BIDCohort 1 - PlaceboCohort 2 - 20 mg QDCohort 2- PlaceboCohort 3 - 5 mg BIDCohort 3- Placebo
The Percent Change From Baseline in PAGI-SYM Subscale Score - Fullness/Early Satiety-24.08 ± 27.288-37.09 ± 34.721-31.45 ± 36.563-47.16 ± 45.857-38.04 ± 37.136-35.73 ± 30.941
Other pre-specifiedThe Change From Baseline in PAGI-SYM Subscale Score - Nausea/Vomiting

Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score and change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

Time frame:
Baseline (last available assessment prior to the first dose of study drug) to Day 14
Reported as:
Mean · score on a scale
The Change From Baseline in PAGI-SYM Subscale Score - Nausea/Vomiting
score on a scaleCohort 1 - 10 mg BIDCohort 1 - PlaceboCohort 2 - 20 mg QDCohort 2- PlaceboCohort 3 - 5 mg BIDCohort 3- Placebo
Baseline2.75 ± 1.0222.97 ± 0.6402.49 ± 0.7653.08 ± 0.9572.74 ± 0.9972.11 ± 1.171
Day 141.78 ± 1.1051.09 ± 0.9671.29 ± 1.1671.08 ± 1.4241.74 ± 1.4980.89 ± 0.509
Change from baseline to Day 14-0.93 ± 1.096-1.88 ± 1.195-1.20 ± 1.030-2.00 ± 1.247-1.00 ± 1.155-1.22 ± 1.678
Other pre-specifiedThe Percent Change From Baseline in PAGI-SYM Subscale Score - Nausea/Vomiting

Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score percent change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

Time frame:
Baseline (last available assessment prior to the first dose of study drug) to Day 14
Reported as:
Mean · Percent change in score
The Percent Change From Baseline in PAGI-SYM Subscale Score - Nausea/Vomiting
Percent change in scoreCohort 1 - 10 mg BIDCohort 1 - PlaceboCohort 2 - 20 mg QDCohort 2- PlaceboCohort 3 - 5 mg BIDCohort 3- Placebo
The Percent Change From Baseline in PAGI-SYM Subscale Score - Nausea/Vomiting-30.39 ± 46.871-60.70 ± 37.490-50.18 ± 45.677-69.55 ± 39.091-39.58 ± 33.284-35.56 ± 62.923
Other pre-specifiedThe Change From Baseline in PAGI-SYM Subscale Score - Bloating

Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score and change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

Time frame:
Baseline (last available assessment prior to the first dose of study drug) to Day 14
Reported as:
Mean · score on a scale
The Change From Baseline in PAGI-SYM Subscale Score - Bloating
score on a scaleCohort 1 - 10 mg BIDCohort 1 - PlaceboCohort 2 - 20 mg QDCohort 2- PlaceboCohort 3 - 5 mg BIDCohort 3- Placebo
Baseline3.84 ± 1.0014.09 ± 0.4913.57 ± 1.3874.00 ± 0.0003.67 ± 0.6123.83 ± 0.289
Day 142.65 ± 1.3142.45 ± 1.6042.47 ± 1.6202.25 ± 1.5002.67 ± 1.6582.67 ± 1.258
Change from baseline to Day 14-1.17 ± 1.227-1.64 ± 1.629-1.10 ± 1.213-1.75 ± 1.500-1.00 ± 1.275-1.17 ± 1.258
Other pre-specifiedThe Percent Change From Baseline in PAGI-SYM Subscale Score - Bloating

Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score percent change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

Time frame:
Baseline (last available assessment prior to the first dose of study drug) to Day 14
Reported as:
Mean · Percent change in score
The Percent Change From Baseline in PAGI-SYM Subscale Score - Bloating
Percent change in scoreCohort 1 - 10 mg BIDCohort 1 - PlaceboCohort 2 - 20 mg QDCohort 2- PlaceboCohort 3 - 5 mg BIDCohort 3- Placebo
The Percent Change From Baseline in PAGI-SYM Subscale Score - Bloating-26.78 ± 39.490-39.77 ± 36.291-36.38 ± 37.429-43.75 ± 37.500-30.16 ± 39.260-30.36 ± 31.288
Other pre-specifiedThe Change From Baseline in PAGI-SYM Subscale Scores - Upper Abdominal Pain

Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score and change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

Time frame:
Baseline (last available assessment prior to the first dose of study drug) to Day 14
Reported as:
Mean · score on a scale
The Change From Baseline in PAGI-SYM Subscale Scores - Upper Abdominal Pain
score on a scaleCohort 1 - 10 mg BIDCohort 1 - PlaceboCohort 2 - 20 mg QDCohort 2- PlaceboCohort 3 - 5 mg BIDCohort 3- Placebo
Baseline2.74 ± 1.2863.00 ± 1.2452.27 ± 1.4133.38 ± 0.2503.17 ± 1.4792.67 ± 0.577
Day 141.82 ± 1.3231.64 ± 1.1201.57 ± 1.4501.25 ± 1.5002.06 ± 1.5301.33 ± 1.155
Change from baseline to Day 14-0.97 ± 1.395-1.36 ± 1.614-0.70 ± 0.978-2.13 ± 1.377-1.11 ± 1.635-1.33 ± 0.577
Other pre-specifiedThe Percent Change From Baseline in PAGI-SYM Subscale Scores - Upper Abdominal Pain

Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score percent change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

Time frame:
Baseline (last available assessment prior to the first dose of study drug) to Day 14
Reported as:
Mean · Percent change in score
The Percent Change From Baseline in PAGI-SYM Subscale Scores - Upper Abdominal Pain
Percent change in scoreCohort 1 - 10 mg BIDCohort 1 - PlaceboCohort 2 - 20 mg QDCohort 2- PlaceboCohort 3 - 5 mg BIDCohort 3- Placebo
The Percent Change From Baseline in PAGI-SYM Subscale Scores - Upper Abdominal Pain-24.47 ± 80.505-50.24 ± 34.116-32.81 ± 41.891-64.29 ± 42.857-37.28 ± 43.374-55.56 ± 38.490
Other pre-specifiedThe Change From Baseline in PAGI-SYM Subscale Score - Lower Abdominal Pain

Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score and change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

Time frame:
Baseline (last available assessment prior to the first dose of study drug) to Day 14
Reported as:
Mean · score on a scale
The Change From Baseline in PAGI-SYM Subscale Score - Lower Abdominal Pain
score on a scaleCohort 1 - 10 mg BIDCohort 1 - PlaceboCohort 2 - 20 mg QDCohort 2- PlaceboCohort 3 - 5 mg BIDCohort 3- Placebo
Baseline2.02 ± 1.3062.64 ± 1.1641.93 ± 1.6242.88 ± 0.2503.11 ± 1.5372.17 ± 1.258
Day 141.25 ± 1.2711.36 ± 1.1641.53 ± 1.3561.50 ± 1.7321.44 ± 1.4241.33 ± 1.155
Change from baseline to Day 14-0.79 ± 1.888-1.27 ± 1.808-0.40 ± 1.021-1.38 ± 1.601-1.67 ± 1.581-0.83 ± 0.764
Other pre-specifiedThe Percent Change From Baseline in PAGI-SYM Subscale Score - Lower Abdominal Pain

Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score percent change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

Time frame:
Baseline (last available assessment prior to the first dose of study drug) to Day 14
Reported as:
Mean · Percent change in score
The Percent Change From Baseline in PAGI-SYM Subscale Score - Lower Abdominal Pain
Percent change in scoreCohort 1 - 10 mg BIDCohort 1 - PlaceboCohort 2 - 20 mg QDCohort 2- PlaceboCohort 3 - 5 mg BIDCohort 3- Placebo
The Percent Change From Baseline in PAGI-SYM Subscale Score - Lower Abdominal Pain-38.38 ± 71.677-25.49 ± 82.970-10.91 ± 56.137-50.00 ± 57.735-52.08 ± 37.456-47.62 ± 50.170
Other pre-specifiedClinical Grading Assessment Scale at Day 14

The Clinical Grading Assessment Scale is a patient and investigator reported outcome instrument for a clinical trial endpoint. Completed at Day 14, the assessment asks subjects about how their stomach/gastroparesis-related problems/symptoms compare to the period before they started treatment in the study based on a 15-point likert scale, where +7 is completely better, 0 is no change, and -7 is very much worse.

Time frame:
Day 14
Reported as:
Count of participants · Participants
Clinical Grading Assessment Scale at Day 14
ParticipantsCohort 1 - 10 mg BIDCohort 1 - PlaceboCohort 2 - 20 mg QDCohort 2- PlaceboCohort 3 - 5 mg BIDCohort 3- Placebo
Subject Responses — Improved1769352
Subject Responses — No change525141
Subject Responses — Worsened110000
Investigator Responses — Improved22811362
Investigator Responses — No change834131
Investigator Responses — Worsened000000

Adverse events

Collected over Approximately 16 days (14 days of study drug treatment plus 2 days of follow-up). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1- 10 mg BID0/30 (0%)0/30 (0%)7/30 (23.3%)
Cohort 2- 20 mg QD0/15 (0%)0/15 (0%)6/15 (40%)
Cohort 3- 5 mg BID0/9 (0%)0/9 (0%)1/9 (11.1%)
Placebo (Pooled)0/18 (0%)0/18 (0%)2/18 (11.1%)
Most frequent other events
Showing 10 of 16
Most frequent other events
EventCohort 1- 10 mg BIDCohort 2- 20 mg QDCohort 3- 5 mg BIDPlacebo (Pooled)
Electrocardiogram QT ProlongationInvestigations1/302/150/90/18
Abdominal Pain LowerGastrointestinal disorders0/300/151/90/18
DiarrhoeaGastrointestinal disorders3/301/150/90/18
ConstipationGastrointestinal disorders0/301/150/90/18
DyspepsiaGastrointestinal disorders0/301/150/90/18
HypoglycaemiaMetabolism and nutrition disorders1/301/150/90/18
SinusitisInfections and infestations0/301/150/90/18
HeadacheNervous system disorders0/301/150/90/18
NauseaGastrointestinal disorders1/300/150/91/18
ArthralgiaMusculoskeletal and connective tissue disorders0/300/150/91/18

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cohort 1- 10 mg BIDCohort 2- 20 mg QDCohort 3- 5 mg BIDPlacebo (Pooled)Total
Mean58.9 ± 7.4458.1 ± 7.0050.7 ± 11.9156.1 ± 11.2357.0 ± 9.25
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1- 10 mg BIDCohort 2- 20 mg QDCohort 3- 5 mg BIDPlacebo (Pooled)Total
Female261181358
Male441514
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1- 10 mg BIDCohort 2- 20 mg QDCohort 3- 5 mg BIDPlacebo (Pooled)Total
Hispanic or Latino19931445
Not Hispanic or Latino1156426
Unknown or Not Reported01001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1- 10 mg BIDCohort 2- 20 mg QDCohort 3- 5 mg BIDPlacebo (Pooled)Total
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American632011
White241271760
More than one race00000
Unknown or Not Reported00011
Region of Enrollment
Region of Enrollment(participants)Cohort 1- 10 mg BIDCohort 2- 20 mg QDCohort 3- 5 mg BIDPlacebo (Pooled)Total
United States301591872
Gastroparesis type
Gastroparesis type(Participants)Cohort 1- 10 mg BIDCohort 2- 20 mg QDCohort 3- 5 mg BIDPlacebo (Pooled)Total
Idiopathic752721
Diabetic231071151
Baseline GEBT T1/2, n(%)
Baseline GEBT T1/2, n(%)(Participants)Cohort 1- 10 mg BIDCohort 2- 20 mg QDCohort 3- 5 mg BIDPlacebo (Pooled)Total
<110 kPCD1150723
>=110 kPCD1962734
Not included in analysis due to test lot recall047415
BMI
BMI(kg/m^2)Cohort 1- 10 mg BIDCohort 2- 20 mg QDCohort 3- 5 mg BIDPlacebo (Pooled)Total
Mean30.16 ± 4.70429.43 ± 6.18928.89 ± 5.85932.00 ± 5.63130.31 ± 5.404
08

Study locations

19 sites
  • Research Site 101
    Chula Vista, California 91910, United States
  • Research Site 114
    Jacksonville, Florida 32224, United States
  • Research Site 117
    Miami, Florida 33134, United States
  • Research Site 118
    Miami, Florida 33183, United States
  • Research Site 111
    Atlanta, Georgia 30322, United States
  • Research Site 110
    Kansas City, Kansas 66045, United States
  • Research Site 103
    Louisville, Kentucky 40202, United States
  • Research Site 112
    Marrero, Louisiana 70072, United States
  • Research Site 104
    Monroe, Louisiana 71201, United States
  • Research Site 102
    Boston, Massachusetts 02215, United States
  • Research Site 121
    Omaha, Nebraska 68134, United States
  • Research Site 113
    Las Vegas, Nevada 89123, United States
  • Research Site 109
    Great Neck, New York 11023, United States
  • Research Site 120
    Winston-Salem, North Carolina 27103, United States
  • Research Site 105
    Tulsa, Oklahoma 74104, United States
  • Research Site 106
    Philadelphia, Pennsylvania 19140, United States
  • Research Site 119
    Summerville, South Carolina 29485, United States
  • Research Site 115
    Rapid City, South Dakota 57702, United States
  • Research Site 107
    Jackson, Tennessee 38305, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2019 to primary completion in Dec 2020, 15 months.

Results were first posted in Mar 2026, 5 years 3 months after primary completion. A results delay was requested in Jul 2021.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2019
First posted
Jul 19, 2019
StartActual
Sep 11, 2019
Primary completionActual
Dec 17, 2020
CompletionActual
Dec 17, 2020
Results delay requested
Jul 16, 2021
Results first posted
Mar 25, 2026
Last update
Mar 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04026997
Lead sponsor
CinDome Pharma, Inc.
Responsible party
Sponsor
First posted
Jul 19, 2019
Start date
Sep 11, 2019
Primary completion
Dec 17, 2020
Completion
Dec 17, 2020
Results posted
Mar 25, 2026
Last update
Mar 25, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: CIN-102 · Deudomperidone

Start the discussion